摘要
目的通过对多西他赛联合氟尿嘧啶治疗进展期胃癌的临床治疗情况,观察其疗效及安全性。方法整群选取2012年1月—2015年1月入该院治疗的168例进展期胃癌患者,随机分为治疗组、对照组,各84例。治疗组采用多西他赛联合氟尿嘧啶进行化疗,对照组则用多西他赛联合替吉奥进行化疗。两组患者均以3周为1个疗程,至少进行2疗程的化疗。治疗结束后观察两组患者的体能改善情况、近期临床疗效以及化疗发生不良反应的情况。结果两组患者化疗近期有效率比较差异无统计学意义(P>0.05),但治疗组体能改善率(83.34%)明显高于对照组(45.24%),两组差异有统计学意义(P<0.05)。结论多西他赛联合氟尿嘧啶治疗进展期胃癌在保证治疗效果的同时,能够较少的影响患者体能状态有临床应用价值。
Objective To observe the efficacy and safety of docetaxel combined with fluorouracil in the treatment of ad-vanced gastric cancer. Methods A total of 168 patients with advanced gastric cancer admitted to this hospital from January 2012 to January 2015 were randomly divided into treatment group and control group with 84 in each one. The treatment group underwent chemotherapy using docetaxel combined with fluorouracil and the control group was treated with chemotherapy using docetaxel combined with S-1 for more than two courses with 3 weeks as one course. The improvement of people＇s physical ability, short-term curative effect and adverse reactions to chemotherapy of the two groups were ob-served after treatment. Results No statistically significant difference can be found in the short-term effective rate of chemotherapy between the two groups, P＆gt;0.05. The improvement rate of people＇s physical ability （83.34% vs 45.24%） was obviously higher in the treatment group than in the control group, and the difference was statistically significant, P〈0.05）. Conclusion Docetaxel combined with fluorouracil in the treatment of advanced gastric cancer is worthy clinical application because it can bring less negative impact on patients＇ physical ability on the basis of keeping a good efficacy.
出处
《中外医疗》
2015年第32期127-128,共2页
China & Foreign Medical Treatment
关键词
多西他赛
氟尿嘧啶
进展期胃癌
临床疗效
Docetaxel
Fluorouracil
Advanced gastric cancer
Clinical efficacy
